Finally, combined administration of TIMP-2 or ERK/MAPK signaling pathway inhibitors and 5-Fu is a promising chemotherapeutic option for the treatment of first time CRC patients as well as relapsed CRC patients previously treated using 5-Fu-based chemotherapy. The gene discussed is TIMP2; the disease is colorectal carcinoma.